Abstract
The human beta coronavirus SARS-CoV-2, causative virus of COVID-19, has infected more than 15 million people globally and continues to spread. Widespread, population level testing to detect active and past infections is critical to curb the COVID-19 pandemic. Antibody (serological) testing is the only option for detecting past infections outside the narrow window accessible to nucleic acid-based tests. However, currently available serological assays commonly lack scalability. Here, we describe the development of a rapid homogenous serological assay for the detection of antibodies to SARS-CoV-2 in patient plasma. We show that the fluorescence-based assay accurately detects seroconversion in COVID-19 patients from less than 1 μL of plasma. Using a cohort of samples from COVID-19 infected or healthy individuals, we demonstrate detection with 100% sensitivity and specificity. This assay addresses an important need for a robust, low barrier to implementation, and scalable serological assay with complementary strengths to currently available serological platforms.
Competing Interest Statement
E.S.F. is a founder, scientific advisory board (SAB) member and equity holder of Civetta Therapeutics, Jengu Therapeutics, and Neomorph, Inc. E.S.F. is an equity holder of C4 Therapeutics. E.S.F. is or has consulted for Novartis, AbbVie, Astellas, Deerfield, EcoR1 and Pfizer. The Fischer lab receives or has received research funding from Novartis, Deerfield and Astellas. R.M. is a scientific advisory board (SAB) member and equity holder of Regenacy Pharmaceuticals, ERX Pharmaceuticals, Frequency Therapeutics. H.Y., R.P.N., D.O., N.C.P., R.M., and E.S.F. are inventors on patent applications related to this work.
Funding Statement
This work was supported by a philanthropic gift from Giving | Grousbeck Fazzalari (to E.S.F.), by NCI R01CA2144608 (to E.S.F), NSF 1830941 and NIH R21AI13298 (both to R.M.). E.S.F. is a Damon-Runyon Rachleff Investigator (DRR-50-18). N.C.P. is supported by the National Science Foundation Graduate Research Fellowship (DGE1745303). This work was supported by a gift from Ms. Enid Schwartz, by the Mark and Lisa Schwartz Foundation, the Massachusetts Consortium for Pathogen Rediness and the Ragon Institute of MGH, MIT and Harvard.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
DFCI Office for Human Research Studies Institutional Review Board determined the proposed activity is not research involving human subjects as defined by DHHS and FDA regulations. iRIS Reference number 371725
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon a request.
